KAM
Krensavage Asset Management Portfolio holdings
AUM
$189M
This Quarter Return
-5.73%
1 Year Return
+19.71%
3 Year Return
+56.44%
5 Year Return
+120.01%
10 Year Return
+215.64%
AUM
$308M
AUM Growth
+$308M
(-17%)
Cap. Flow
-$34.1M
Cap. Flow
% of AUM
-11.07%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
12
New
–
Increased
3
Reduced
7
Closed
2
Top Buys
| 1 |
Amgen
AMGN
|
$4M |
| 2 |
United Therapeutics
UTHR
|
$3.51M |
| 3 |
Enanta Pharmaceuticals
ENTA
|
$298K |
Top Sells
| 1 |
Merck
MRK
|
$34.3M |
| 2 |
McKesson
MCK
|
$5.15M |
| 3 |
Biogen
BIIB
|
$805K |
| 4 |
Gilead Sciences
GILD
|
$513K |
| 5 |
Elanco Animal Health
ELAN
|
$417K |
Sector Composition
| 1 | Healthcare | 97.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
McKesson
MCK
$85.4B
| $50.2M | 16.28% | 373,297 -38,358 | -9% | -$5.15M |
|
|
2
United Therapeutics
UTHR
$13.8B
| $43M | 13.94% | 550,299 +45,000 | +9% | +$3.51M |
|
|
3
Biogen
BIIB
$19.4B
| $41.3M | 13.4% | 176,556 -3,444 | -2% | -$805K |
|
|
4
Enanta Pharmaceuticals
ENTA
$180M
| $40.5M | 13.13% | 479,576 +3,534 | +0.7% | +$298K |
|
|
5
Amgen
AMGN
$155B
| $39.7M | 12.88% | 215,402 +21,732 | +11% | +$4M |
|
|
6
Gilead Sciences
GILD
$140B
| $37.2M | 12.09% | 551,237 -7,590 | -1% | -$513K |
|
|
7
Elanco Animal Health
ELAN
$9.12B
| $30.1M | 9.78% | 891,851 -12,351 | -1% | -$417K |
|
|
SRGA
8
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $16.7M | 5.4% | 3,917,744 -54,253 | -1% | -$231K |
|
|
IVC
9
DELISTED
Invacare Corporation
IVC
| $6.91M | 2.24% | 1,331,409 -18,332 | -1% | -$95.1K |
|
10
Avanos Medical
AVNS
$554M
| $2.59M | 0.84% | 59,378 -2,679 | -4% | -$117K |
|
|
STRR
11
DELISTED
Star Equity Holdings
STRR
| – | – | -295,168 | Closed | -$269K |
|
|
12
Merck
MRK
$210B
| – | – | -412,809 | Closed | -$34.3M |
|